NYNoriaki Yamamoto

Noriaki Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noriaki Yamamoto has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is Plasma Total Antioxidant Capacity Elevated in Professional Soccer Athletes?: A Cross-Sectional Study

    by Tomoharu Mochizuki, Takashi Ushiki, Hikaru Kanome, Takumu Tsuchida, Mami Osawa, Misato Sato, Hajime Ishiguro, Tatsuya Suwabe, Satoshi Watanabe, Go Omori, et al.

    Owing to its ability to promote early recovery, platelet-rich plasma (PRP) is a popular regenerative therapy for treating sports injuries. However, its scientific basis has not yet been fully established. To bridge this gap, we focused on systemic antioxidant capacity, which suppresses exacerbated inflammation. Plasma total antioxidant capacity (TAC) in male professional soccer athletes (n = 30) was assessed alongside body composition measurements and compared with that of non-athletes (n = 31). Metabolic and inflammatory conditions were examined using erythrocyte sedimentation rate and plasma lactate, glucose, and protein levels. TAC levels were similar in both groups. Moderate correlations were observed between TAC and body fat percentage, skeletal muscle percentage, and basal metabolic rate in the control group, but not in the pro-athlete group, which exhibited superior body composition indices. These findings suggest that TAC levels may not directly influence PRP therapy in athletes. However, when compared with TAC levels calculated using correlations obtained in controls, the measured TAC levels (329.3 mM) were substantially higher than the compensated levels (62.5 mM for basal metabolic rate) in pro-athletes. This analytical approach indicates that TAC may theoretically be elevated to higher levels in pro-athletes when evaluated using non-athlete-based scales.

  • Open Access

    Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone

    by Naoko Hidaka, Yuko Oyama, Minae Koga, Naoki Kondo, Yoichi Yasunaga, Taketoshi Shimakura, Noriaki Yamamoto, Hideaki E Takahashi, Yoichi Iwafuchi, So Watanabe, et al.

    Excess fibroblast growth factor 23 (FGF23), a mature osteocyte-derived phosphaturic hormone, causes chronic hypophosphatemic osteomalacia in adults. This rare condition was recently reported in 2 alcoholic patients, with marked improvement upon cessation of alcohol consumption, suggesting a link between alcohol and FGF23-related hypophosphatemia within the highly limited cases. This study aimed to investigate whether the source of excess FGF23 in alcohol-induced FGF23-related hypophosphatemic osteomalacia is the bone or the other organs. To achieve this goal, an immunohistochemical approach for the bone obtained from a patient was employed. Initial attempts at quantifying FGF23 in the bone using conventional immunohistochemistry (IHC) faced issues in quantifiability and sensitivity for low FGF23 expression levels. Therefore, next-generation IHC with phosphor-integrated dots (PIDs) was applied, which enabled the quantification of FGF23 expression in the bone across a broad range. Preliminary analyses using IHC with PIDs on normal bone samples (n = 12) provided a reference level (154.5 PID particles per cell). IHC with PIDs quantified suppressed physiological FGF23 expression in the bone samples from 3 patients with tumor-induced osteomalacia, where FGF23 is oversecreted from a tumor (13.6 PID particles per cell). Subsequently, bone samples obtained from a 70-yr-old male with alcohol-induced FGF23-related hypophosphatemic osteomalacia were analyzed, showing a higher number of PID particles per cell (199.4 PID particles per cell) than the reference level. This study suggests that orthotopic, bone-derived FGF23 is implicated in alcohol-induced FGF23-related hypophosphatemic osteomalacia. Furthermore, the study also demonstrated that highly sensitive IHC with PIDs could aid in the differential diagnosis of FGF23-related hypophosphatemia of unknown origin. Specifically, a bone sample with a low number of PID particles per cell indicates an excess ectopic secretion of FGF23; a bone sample with a normal to high number of PID particles per cell indicates an excess orthotopic secretion of FGF23.


  • Open Access

    Management of Osteoporosis Treatment and Osteoporosis Liaison Service

    by Noriaki Yamamoto

    FLSは多職種連携によるチーム医療であり,骨折リスクの高い高齢者の特定から評価,治療の開始と継続まで,病院から地域に広がる骨折患者の継続的な管理を行い,二次性骨折を最小限にするための医療システムである.OLSはさらに骨粗鬆症の予防や治療の教育や啓発など広範囲に骨粗鬆症診療に貢献することが期待されている.薬剤治療は骨折予防の基本的介入方法であり,医療側が各薬剤の特徴を理解し,適正な薬剤選択とモニタリングを行うことが必要である.

  • Open Access

    Elevated IL-1β and Comparable IL-1 Receptor Antagonist Levels Are Characteristic Features of L-PRP in Female College Athletes Compared to Male Professional Soccer Players

    by Tomoharu Mochizuki, Takashi Ushiki, Katsuya Suzuki, Misato Sato, Hajime Ishiguro, Tatsuya Suwabe, Satoshi Watanabe, Mutsuaki Edama, Go Omori, Noriaki Yamamoto, et al.

    Autologous platelet-rich plasma (PRP) therapy has been becoming popular for the treatment of musculotendinous injuries among athletes. However, for individual and practical variations, clinical success is hardly predictable. To overcome this difficulty, we have been exploring possible criterion candidates for monitoring its clinical effectiveness. In this study, we focused on sex-based differences in young elite athletes and compared the biochemical compositions of their PRP. Leukocyte-rich PRP (L-PRP) was manually prepared from blood samples collected from male professional soccer players (mPSPs) (n = 25) and female college athletes (fCAs) (n = 36). Platelet-derived growth factor-BB (PDGF-BB), transforming-growth factor-β1 (TGFβ1), platelet factor-4 (PF4), interleukin-1β (IL-1β), and IL-1 receptor antagonist (IL-1RA) were quantified using an enzyme-linked immunosorbent assay. The levels of PDGF-BB, TGFβ1, and PF4 in L-PRP were significantly higher in mPSPs than in fCAs. Conversely, IL-1β and IL-1RA were detected at significantly and slightly higher levels, respectively, in fCAs than in mPSPs. Our findings suggest that, even though L-PRP from fCAs may have lower potential to induce cell growth and differentiation than that of mPSPs, due to the latter’s higher capacity to control inflammation, it does not necessarily imply that PRP treatment in fCAs is less effective. Thus, these cytokine levels should be checked before PRP therapy.


  • Open Access

    Characterization of Leukocyte- and Platelet-Rich Plasma Derived from Female Collage Athletes: A Cross-Sectional Cohort Study Focusing on Growth Factor, Inflammatory Cytokines, and Anti-Inflammatory Cytokine Levels

    by Tomoharu Mochizuki, Takashi Ushiki, Katsuya Suzuki, Misato Sato, Hajime Ishiguro, Tatsuya Suwabe, Mutsuaki Edama, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    Platelet-rich plasma (PRP) has been increasingly used in sports medicine owing to its various advantages. The purpose of our project was to standardize the parameters before performing large-scale clinical trials in the near future to precisely evaluate individual PRP quality. To examine the effects of regular exercise on PRP quality, this study focused on young female athletes, who have been relatively less studied. Blood samples were obtained from female college athletes (n = 35) and ordinary healthy adults (n = 30), which were considered as controls, and leukocyte-rich PRP (L-PRP) was prepared manually. Body composition indices were determined using a bathroom weight scale equipped with an impedance meter. Growth factors and cytokines were quantified using ELISA kits. Platelet-derived growth factor-BB (PDGF-BB) and Transforming-growth factors β1 (TGFβ1) levels (per platelet) in L-PRP were significantly lower in female athletes than in controls. In contrast, Interleukin-1β and Interleukin 1 receptor antagonist (IL-1RA) levels (per platelet and L-PRP) in L-PRP were significantly higher in athletes, and this difference was more prominent in IL-1RA. These findings suggest that L-PRP from athletes may facilitate the inflammatory phase of the healing process by regulating the pro-inflammatory and anti-inflammatory balance. These chemical compositions can be adopted as “must-check” parameters to characterize individual PRP preparations prior to clinical trials.


  • Open Access

    Platelet polyphosphate and energy metabolism in professional male athletes (soccer players): A cross‐sectional pilot study

    by Takashi Ushiki, Tomoharu Mochizuki, Katsuya Suzuki, Masami Kamimura, Hajime Ishiguro, Satoshi Watanabe, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    Human platelet polyphosphate (polyP) is a multifunctional molecule; however, its functions are not yet fully understood. A recent study demonstrated that similar to skeletal muscle, polyP is involved in energy metabolism in platelets, which suggests that well‐trained athletes may exhibit elevated platelet polyP levels for energy storage. To test this hypothesis, we quantified platelet polyP along with NADH, a component involved in ATP production in non‐trained and well‐trained male Japanese participants of the same generation. Washed platelets were prepared from the venous blood of young, healthy, non‐athletes, and professional soccer players (pro‐athletes). NADH and polyP levels were spectrophotometrically determined using tetrazolium reduction and fluorometrically determined using 4′,6‐diamidino‐2‐phenylindole at the excitation/emission wavelengths of 425/525 nm. Body weight and impedances were measured simultaneously. Statistical analyses were performed using the Mann–Whitney U test and Spearman correlation coefficient. Although basal metabolic rate levels were significantly higher, platelet polyP levels were significantly lower in pro‐athletes than in that in non‐athletes. No significant differences were detected in other body compositions or platelet indices between the two groups. The pro‐athlete group showed a moderate, nearly significant correlation (R = 0.439; p = 0.0512) between platelet polyP and NADH levels. Taken together with the weak correlation data between polyP and body mass index, it is suggested that platelet polyP levels may be influenced by platelet and body energy metabolic activity. Further biochemical studies are needed to elucidate this mechanism.


  • Neoadjuvant teriparatide therapy targeting the osteoporotic spine: influence of administration period from the perspective of bone histomorphometry

    by Kimihiko Sawakami, Kei Watanabe, Kazuhiro Hasegawa, Noriaki Yamamoto, Taketoshi Shimakura, Masayuki Ohashi, Hirokazu Shoji, Tatsuki Mizouchi, Yuki Tanaka, Hiroyuki Segawa, et al.

    OBJECTIVE: Teriparatide (TPTD) is a potent promoter of early-stage osteogenesis and may be a useful adjuvant therapy to reduce complications related to bone fragility in spinal surgery patients with osteoporosis. However, effective neoadjuvant TPTD therapy regimens remain poorly understood. This study aimed to examine the effect of preoperative TPTD administration on cancellous bone with bone histomorphometry and to clarify the timing of preoperative TPTD administration for patients with spinal fusion and osteoporosis. METHODS: In this longitudinal multicenter study, 57 patients with spinal fusion and osteoporosis, who consented to undergo iliac biopsy, were allocated to the following treatment groups: neoadjuvant TPTD therapy group (n = 42) and no neoadjuvant therapy (NTC) group (n = 15). Patients in the TPTD group were categorized into subgroups on the basis of duration of preoperative TPTD administration, as follows: 1 month (n = 9), 2 months (n = 8), 3 months (n = 9), 4 months (n = 7), and 6 months (n = 9). All patient samples were preoperatively double labeled with tetracycline, and iliac biopsies were performed during spinal fusion surgery. Histomorphometric analyses were performed on nondecalcified, thin-sliced specimens. Specimens were classified on the basis of TPTD administration duration and subsequently compared with those of the NTC group. Postoperative complications and Oswestry Disability Index scores were evaluated at 1 and 2 years after surgery. RESULTS: There were no demographic differences between groups. Mineralizing surface/bone surface, a key parameter of dynamic bone formation, started to increase after 1 month of TPTD administration; this increase became significant after 3 months of administration and peaked at 4 months, with a 6-fold increase relative to that of the NTC group. The patients who received preoperative TPTD for 3 months or more had superior clinical results in terms of the osteoporotic complication rate and Oswestry Disability Index scores, except for bisphosphonate-pretreated patients. CONCLUSIONS: When considering neoadjuvant TPTD therapy, the authors recommend at least 3 months of preoperative administration to provide a more substantial anabolic effect from the early postoperative stage.


  • Mineralization Impairment Due to Vitamin D Deficiency in Bone Histomorphometry

    by Noriaki Yamamoto, Yoshinori Takahashi, Taketoshi Shimakura, Hideaki E. Takahashi

  • Bone Histomorphometry in Miscellaneous Metabolic Diseases: Hepatic C-Associated Osteosclerosis, IgG4-Related Disease, and Ehlers–Danlos Syndrome

    by Noriaki Yamamoto, Taketoshi Shimakura, Hideaki E. Takahashi, Nobuhiro Miyamura, Chieko Kawakita, Masaru Kinomura, Kenichiro Asano, Masashi Uehara, Jun Takahashi, Tomoki Kosho

  • Open Access

    A Resected Case of Uterine Metastasis after Curative Gastrectomy for Gastric Cancer

    by Kai Goyo, Isao Nozaki, Shinji Hato, Tetsuya Kagawa, Noriaki Yamamoto, Takafumi Sugawara

    症例は72歳の女性.胃癌に対して根治切除術と術後補助化学療法を施行後6年目のCTで,既知の子宮筋腫の急激な増大と直腸壁肥厚を認めた.下部内視鏡検査で上部直腸に壁外性圧排所見があり,同部からの生検で印環細胞癌が検出されたため,胃癌再発と診断した.子宮頸部擦過・内膜細胞診では悪性所見は認めなかったが,胃癌の子宮転移を疑い,今後さらに増大すると消化管閉塞が危惧されたため,開腹手術を行った.子宮は小児頭大であり,子宮・両側付属器切除術を施行した.小腸・直腸および腸間膜に複数の腹膜結節がみられたが,狭窄の可能性の高い小腸病変のみにバイパス手術を施行した.病理組織学的に子宮筋腫内と子宮体部・頸部の間質内にびまん性に増殖する印環細胞を認め,胃癌の子宮転移と診断した.術後経過は良好で17日目に退院し,その後化学療法を導入した.2回目の手術より11カ月経過したが担癌生存中である.